在阿尔茨海默氏症大脑退化中准CaN/NFAT
Joanna Mackiewicz1, Malwina Lisek1, Tomasz Boczek1
1Department of Molecular Neurochemistry, Medical University of Lodz, Lodz, Poland.
Frontiers in immunology
|December 11, 2023
概括
向激活T细胞 (NFAT) 途径的氨尿素/核因子可以治疗阿尔茨海默病 (AD). 这一途径驱动着炎症和神经退行,抑制它在阿尔茨海默病的临床前模型中显示出希望.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是认知能力下降,β-粉样质斑块和tau结.
- 持续的炎症反应是阿尔茨海默病的一个关键特征,可能会加剧病理,并将初始斑块沉积与以后的结发展联系起来.
研究的目的:
- 讨论最近关于激活T细胞 (CaN/NFAT) 信号传导的氨尿素/核因子对AD进展的贡献的发现.
- 突出针对AD治疗的CaN/NFAT通路的治疗潜力.
主要方法:
- 关于AD中CaN/NFAT信号的现有文献的综述.
- 对临床前阿尔茨海默病模型和死后脑组织研究的分析.
- 检查CaN/NFAT抑制剂对AD病理学的影响.
主要成果:
- 异常的CaN/NFAT信号传递与AD病理,如神经元亡,突触缺陷和质细胞激活有关.
- NFAT异型在AD进展中发挥作用,与认知能力下降相关.
- 在临床前模型中抑制CaN/NFAT信号减少了β-粉样神经毒性和神经炎症,缓解了AD的一些症状.
结论:
- 该CaN/NFAT信号通路是阿尔茨海默病进展的重要贡献者.
- 准这种途径为缓解AD病理和症状提供了一个有希望的治疗策略.
相关概念视频
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492